Alkermes plc. Net Cash Provided by (Used in) Operating Activities, Continuing Operations
Alkermes plc. (ALKS) reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of -$13.75 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-04-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2017-04-27
- Alkermes plc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-03-31 was -$13.75M.
- Alkermes plc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2016-12-31 was $7.56M, a 212.96% increase year-over-year.
- Alkermes plc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2016-09-30 was $14.73M.
- Alkermes plc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2016-06-30 was -$28.88M.
- Alkermes plc. net cash provided by (used in) operating activities, continuing operations for fiscal 2016 was -$63.80M.
- Alkermes plc. net cash provided by (used in) operating activities, continuing operations for fiscal 2015 was -$40.36M, a 462.33% decline from fiscal 2014.
- Alkermes plc. net cash provided by (used in) operating activities, continuing operations for fiscal 2014 was $11.14M, a 92.45% decline from fiscal 2013.
- Alkermes plc. net cash provided by (used in) operating activities, continuing operations for fiscal 2013 was $147.53M.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-03-31 | -$13.75M 10-Q · filed 2017-04-27 | -$6.19M derived: sum of 2 quarters · filed 2017-04-27 | $8.54M derived: sum of 3 quarters · filed 2017-04-27 | -$20.34M derived: sum of 4 quarters · filed 2017-04-27 |
| 2016-12-31 | $7.56M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $22.29M derived: sum of 2 quarters · filed 2017-02-17 | -$6.59M derived: sum of 3 quarters · filed 2017-02-17 | -$63.80M 10-K · filed 2017-02-17 |
| 2016-09-30 | $14.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | -$14.15M derived: sum of 2 quarters · filed 2016-11-02 | -$71.36M 10-Q · filed 2016-11-02 | -$68.94M derived: sum of 4 quarters · filed 2017-04-27 |
| 2016-06-30 | -$28.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | -$86.09M 10-Q · filed 2016-07-28 | -$83.68M derived: sum of 3 quarters · filed 2017-04-27 | -$113.12M derived: sum of 4 quarters · filed 2017-04-27 |
| 2016-03-31 | -$57.21M 10-Q · filed 2017-04-27 | -$54.80M derived: sum of 2 quarters · filed 2017-04-27 | -$84.25M derived: sum of 3 quarters · filed 2017-04-27 | -$99.65M derived: sum of 4 quarters · filed 2017-04-27 |
| 2015-12-31 | $2.42M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | -$27.03M derived: sum of 2 quarters · filed 2017-02-17 | -$42.44M derived: sum of 3 quarters · filed 2017-02-17 | -$40.36M 10-K · filed 2017-02-17 |
| 2015-09-30 | -$29.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | -$44.85M derived: sum of 2 quarters · filed 2016-11-02 | -$42.77M 10-Q · filed 2016-11-02 | -$29.13M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | -$15.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | -$13.33M 10-Q · filed 2016-07-28 | $314.00K derived: sum of 3 quarters · filed 2017-02-17 | -$7.50M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | $2.08M 10-Q · filed 2016-04-28 | $15.72M derived: sum of 2 quarters · filed 2017-02-17 | $7.91M derived: sum of 3 quarters · filed 2017-02-17 | $16.69M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $13.64M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $5.83M derived: sum of 2 quarters · filed 2017-02-17 | $14.61M derived: sum of 3 quarters · filed 2017-02-17 | $11.14M 10-K · filed 2017-02-17 |
| 2014-09-30 | -$7.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-29 | $968.00K derived: sum of 2 quarters · filed 2015-10-29 | -$2.50M 10-Q · filed 2015-10-29 | $35.60M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | $8.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-30 | $5.30M 10-Q · filed 2015-07-30 | $43.41M derived: sum of 3 quarters · filed 2016-02-25 | $84.78M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | -$3.47M 10-Q · filed 2015-04-30 | $34.63M derived: sum of 2 quarters · filed 2016-02-25 | $76.00M derived: sum of 3 quarters · filed 2016-02-25 | $88.75M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | $38.11M derived: 10-K 9 month − 10-Q 6 month · filed 2016-02-25 | $79.47M derived: sum of 2 quarters · filed 2016-02-25 | $92.22M 10-K · filed 2016-02-25 | $147.53M 10-K · filed 2016-02-25 |
| 2013-09-30 | $41.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-10-31 | $54.12M 10-Q · filed 2013-10-31 | $109.42M 10-Q · filed 2014-10-29 | $135.62M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | $12.75M 10-Q · filed 2013-07-25 | $68.05M 10-Q · filed 2014-07-31 | $94.25M derived: sum of 3 quarters · filed 2015-02-24 | $144.00M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | $55.30M 10-Q · filed 2014-04-30 | $81.50M derived: sum of 2 quarters · filed 2015-02-24 | $131.25M derived: sum of 3 quarters · filed 2015-02-24 | $126.55M 10-K · filed 2015-02-24 |
| 2012-12-31 | $26.20M derived: 10-K 9 month − 10-Q 6 month · filed 2015-02-24 | $75.95M derived: sum of 2 quarters · filed 2015-02-24 | $71.25M 10-K · filed 2015-02-24 | $86.53M derived: sum of 4 quarters · filed 2015-02-24 |
| 2012-09-30 | $49.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-10-31 | $45.05M 10-Q · filed 2013-10-31 | $60.33M derived: sum of 3 quarters · filed 2014-02-27 | $58.12M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | -$4.70M 10-Q · filed 2013-07-25 | $10.58M derived: sum of 2 quarters · filed 2014-02-27 | $8.37M derived: sum of 3 quarters · filed 2014-02-27 | $11.08M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $15.28M derived: 10-KT 12 month − 10-Q 9 month · filed 2014-02-27 | $13.07M derived: sum of 2 quarters · filed 2014-02-27 | $15.78M derived: sum of 3 quarters · filed 2014-02-27 | -$2.48M 10-KT · filed 2014-02-27 |
| 2011-12-31 | -$2.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-01-31 | $495.00K derived: sum of 2 quarters · filed 2013-01-31 | -$17.76M 10-Q · filed 2013-01-31 | |
| 2011-09-30 | $2.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-11-01 | -$15.55M 10-Q · filed 2012-11-01 | ||
| 2011-06-30 | -$18.26M 10-Q · filed 2012-07-26 | |||
| 2011-03-31 | -$5.91M 10-K · filed 2013-05-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |